David Shaw’s Unity Biotechnology UBX Stock Holding History

David Shaw’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,015	Closed	-$15K	–	5951
2021 Q4	$15K	Sell	1,015 -10,527	-91%	-$230K	﹤0.01%	5312
2021 Q3	$346K	Buy	11,542 +6,032	+109%	+$213K	﹤0.01%	4281
2021 Q2	$256K	Buy	+5,510	New	+$265K	﹤0.01%	4348
2021 Q1	–	Sell	-1,555	Closed	-$81K	–	4505
2020 Q4	$81K	Buy	+1,555	New	+$75K	﹤0.01%	3831
2020 Q3	–	Sell	-1,560	Closed	-$135K	–	4178
2020 Q2	$135K	Buy	+1,560	New	+$116K	﹤0.01%	3855
2020 Q1	–	Sell	-3,471	Closed	-$250K	–	4280
2019 Q4	$250K	Buy	+3,471	New	+$245K	﹤0.01%	3709
2018 Q4	–	Sell	-1,122	Closed	-$183K	–	3998
2018 Q3	$183K	Buy	+1,122	New	+$185K	﹤0.01%	3571

Other funds holding UBX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

PVI

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FFVM

Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return

David Shaw's UBX Position: Q1 2022 in Review

David Shaw sold out of Unity Biotechnology (UBX) in Q1 2022, closing a stake of 1,015 shares — an estimated $15K sold.

David Shaw first reported a position in UBX in Q3 2018 and held it in 7 quarters. The position peaked at $346K in Q3 2021. 70 funds tracked by Wall St. Rank hold UBX as of Q1 2022.

David Shaw reported no remaining Unity Biotechnology position as of Q1 2022 after selling out during the quarter.
David Shaw sold 1,015 Unity Biotechnology shares in Q1 2022, an estimated $15K.
David Shaw first reported a position in Unity Biotechnology in Q3 2018 and held it in 7 quarters.
David Shaw's Unity Biotechnology position peaked at $346K in Q3 2021.
70 funds tracked by Wall St. Rank held Unity Biotechnology as of Q1 2022.

Based on D.E. Shaw & Co's 13F filing for Q1 2022, filed 16 May 2022.